鉴定氧化捐赠达沙替尼衍生物与眼内压力降低和老化活动
Zhongshu Pan1,2, Jiaming Zhang1,2, Haoyu Zuo2
1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, P. R. China.
Journal of medicinal chemistry
|April 14, 2025
概括
开发了新的达沙替尼衍生物,以向高眼内压 (IOP) 和青光眼的衰老. 化合物2e在临床前模型中表现出强大的双重内血压降低和老化作用,提供了有前途的玻璃眼癌治疗方法.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 玻璃眼症的特征是眼内压力升高 (IOP) 和细胞衰老.
- 现有的治疗方法可能无法完全解决这些潜在病理,特别是在老年人群中.
研究的目的:
- 设计,合成和评估新型的氧化 (NO) 捐赠达沙替尼衍生物作为潜在的玻璃眼治疗方法.
- 研究这些化合物在降低内血压和清除衰老细胞方面的双重有效性.
主要方法:
- 合成了两系列无NO捐赠达沙替尼衍生物 (1a-f,2a-f).
- 在体外评估NO释放,3',5'-循环瓜诺辛单酸盐 (cGMP) 水平,以及状网状细胞中的老化活性.
- 在慢性眼高血压 (COHT) 青光斑小鼠模型中对化合物2e的体内评估,评估衰老细胞的消除,视网膜质细胞 (RGC) 存活率,IOP和视觉功能.
主要成果:
- 化合物2e在体外表现出有效的NO释放,增加了cGMP水平,并保持了老化活性.
- 在COHT小鼠中,局部给药2e显著减少了衰老细胞,保留了RGCs,降低了IOP,并保护了视觉功能.
- 化合物2e的治疗效果优于达沙替尼,在老年COHT小鼠中特别明显,严重的RGC损失.
结论:
- 双 IOP 降低和 senolytic 属性代表了一种有前途的治疗策略,对玻璃眼.
- 无NO捐赠的达沙提尼布衍生物2e显示出治疗青光瘤的巨大潜力,特别是在老年患者中.
- 针对高的IOP和衰老,提供了一种新的眼光瘤管理方法.
相关概念视频
Antihypertensive Drugs: Vasodilators
428
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
428
Open Angle Glaucoma: Treatment
363
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
363
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
394
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
394
Antihypertensive Drugs: Direct Renin Inhibitors
445
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
445
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
94
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
94
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
93
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
93


